Search

A recent study conducted by Guangzhou Medical University in China has identified a potential new treatment for idiopathic pulmonary fibrosis (IPF), a progressive lung disease with limited treatment options. The researchers discovered that chlorquinaldol, an antimicrobial drug, effectively inhibits the transition of fibroblasts to myofibroblasts and mitigates pulmonary fibrosis in mice. The study also revealed that chlorquinaldol targets methionine synthase reductase (MTRR), a protein associated with IPF, and activates the MTRR-mediated methionine cycle, which counteracts the fibrotic effect. These findings suggest that chlorquinaldol may serve as a novel antifibrotic medication, and targeting MTRR holds promise as a therapeutic strategy for pulmonary fibrosis. [Extracted from the article]

Keywords: Guangzhou; People's Republic of China; Asia; Digestive System Diseases and Conditions; Drugs and Therapies; Health and Medicine; Inflammation; Nephrology; Peritoneal Diseases and Conditions; Peritonitis; Therapeutics; Therapy EN Guangzhou People's Republic of China Asia Digestive System Diseases and Conditions Drugs and Therapies Health and Medicine Inflammation Nephrology Peritoneal Diseases and Conditions Peritonitis Therapeutics Therapy 1165 1165 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Fresh data on Digestive System Diseases and Conditions - Peritonitis are presented in a new report. Importantly, treatment with SB-222200 demonstrates alleviation of NLRP3-dependent inflammatory diseases in mouse models, such as monosodium urate crystal-induced peritonitis and dextran sulfate sodium-induced acute intestinal inflammation." According to the news editors, the research concluded: "Therefore, SB-222200 holds promise as a lead compound for the development of NLRP3 inhibitors to combat NLRP3-driven disease and serves as a versatile tool for pharmacologically investigating NLRP3 biology.". [Extracted from the article]